Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Surgery Partners (SGRY) over the last 12 years, with Q3 2025 value amounting to $39.5 million.

  • Surgery Partners' Depreciation & Amortization (CF) fell 2131.47% to $39.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $150.0 million, marking a year-over-year increase of 13.35%. This contributed to the annual value of $152.6 million for FY2024, which is 2921.25% up from last year.
  • Surgery Partners' Depreciation & Amortization (CF) amounted to $39.5 million in Q3 2025, which was down 2131.47% from $40.3 million recorded in Q2 2025.
  • In the past 5 years, Surgery Partners' Depreciation & Amortization (CF) ranged from a high of $50.2 million in Q3 2024 and a low of $22.7 million during Q4 2021
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $29.8 million (2022), whereas its average is $31.6 million.
  • In the last 5 years, Surgery Partners' Depreciation & Amortization (CF) surged by 7370.24% in 2024 and then plummeted by 2131.47% in 2025.
  • Over the past 5 years, Surgery Partners' Depreciation & Amortization (CF) (Quarter) stood at $22.7 million in 2021, then soared by 30.4% to $29.6 million in 2022, then grew by 5.07% to $31.1 million in 2023, then increased by 9.0% to $33.9 million in 2024, then rose by 16.52% to $39.5 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $39.5 million for Q3 2025, versus $40.3 million for Q2 2025 and $36.3 million for Q1 2025.